Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Files An 8-K Results of Operations and Financial Condition
ITEM2.02
|
Results of Operations and Financial Condition. |
On May 10, 2017, Intra-Cellular Therapies, Inc. (the Company)
announced its financial results for the first quarter ended March
31, 2017, and provided a corporate update.
A copy of the Companys press release containing such
announcements is attached hereto as Exhibit 99.1. The information
in the press release set forth in the first four paragraphs under
the heading First Quarter 2017 Financial Results, together with
the condensed consolidated financial information included in the
press release, are incorporated by reference into this Item 2.02
of this Current Report on Form 8-K.
| ITEM8.01 | Other Events. |
In the press release dated May 10, 2017, the Company also
provided a corporate update. The information set forth in the
last paragraph under the heading First Quarter 2017 Financial
Results and under the headings Corporate Update and About
Intra-Cellular Therapies, together with the forward-looking
statement disclaimer at the end of the press release, are
incorporated by reference into this Item 8.01 of this Current
Report on Form 8-K.
| ITEM9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
|
Exhibit Number |
Description |
|
| 99.1 | Press release dated May 10, 2017. |
The press release may contain hypertext links to information on
our website. The information on our website is not incorporated
by reference into this Current Report on Form 8-K and does not
constitute a part of this Form 8-K.
The portions of the press release incorporated by reference into
Item 8.01 of this Current Report on Form 8-K are being filed to
Item 8.01. The remaining portions of the press release are being
furnished to Item 2.02 of this Current Report on Form 8-K and
shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act
except as shall be expressly set forth by specific reference in
such filing.
About Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company’s pipeline includes approximately two product candidates in clinical development and two product candidates in advanced pre-clinical testing. Its platform includes ITI-007 platform and phosphodiesterase (PDE) Inhibitor Platform. It is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, behavioral disturbances associated with dementia, autism and other CNS diseases. Its ITI-007 platform also includes long acting injectable (LAI) program, and IC200131 program for mood and other disorders. Its PDE Inhibitor Platform includes PDE1 program and PDE2 and PDE9 programs. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Recent Trading Information
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) closed its last trading session down -0.02 at 9.26 with 351,682 shares trading hands.
